V Chiappetta, C Cantón, C Pruzzo, C Lanusse, L Alvarez, L Ceballos
{"title":"Albendazole and Clorsulon in Fasciola hepatica Control: Integrated Pharmacokinetic and Flukicidal Eficacy Assessment in Sheep.","authors":"V Chiappetta, C Cantón, C Pruzzo, C Lanusse, L Alvarez, L Ceballos","doi":"10.1111/jvp.70009","DOIUrl":null,"url":null,"abstract":"<p><p>Fasciola hepatica causes fasciolosis, a growing zoonotic disease that affects both livestock and humans worldwide. The main strategy to control fasciolosis in livestock animals, is based on drugs such as triclabendazole (TCBZ), albendazole (ABZ), clorsulon (CLOR), nitroxynil, closantel, and rafoxanide. Only TCBZ is available for F. hepatica control in human medicine and its resistance is growing. The use of drug combinations has been proposed as a strategy to delay it. This study compares the pharmacokinetics and flukicidal efficacy of ABZ + CLOR when administered together or separately in sheep infected with F. hepatica. Enhanced systemic exposure of the ABZ sulphoxide metabolite was observed after the co-administration ABZ + CLOR compared to the ABZ alone treatment. The CLOR disposition kinetics was not affected by its co-administration with ABZ. The flukicidal clinical efficacy was 85% (ABZ), 92% (CLOR) and 100% (ABZ + CLOR), respectively. The work described here contributes to the characterization of the disposition kinetics of both flukicidal molecules showing that the combined ABZ and CLOR therapy may enhance the efficacy against F. hepatica in sheep.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jvp.70009","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Fasciola hepatica causes fasciolosis, a growing zoonotic disease that affects both livestock and humans worldwide. The main strategy to control fasciolosis in livestock animals, is based on drugs such as triclabendazole (TCBZ), albendazole (ABZ), clorsulon (CLOR), nitroxynil, closantel, and rafoxanide. Only TCBZ is available for F. hepatica control in human medicine and its resistance is growing. The use of drug combinations has been proposed as a strategy to delay it. This study compares the pharmacokinetics and flukicidal efficacy of ABZ + CLOR when administered together or separately in sheep infected with F. hepatica. Enhanced systemic exposure of the ABZ sulphoxide metabolite was observed after the co-administration ABZ + CLOR compared to the ABZ alone treatment. The CLOR disposition kinetics was not affected by its co-administration with ABZ. The flukicidal clinical efficacy was 85% (ABZ), 92% (CLOR) and 100% (ABZ + CLOR), respectively. The work described here contributes to the characterization of the disposition kinetics of both flukicidal molecules showing that the combined ABZ and CLOR therapy may enhance the efficacy against F. hepatica in sheep.
期刊介绍:
The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.